Fate Therapeutics INC (FATE) Holder Artal Group Sa Cut Position

Investors sentiment decreased to 1.08 in Q1 2019. Its down 0.52, from 1.6 in 2018Q4. It worsened, as 11 investors sold FATE shares while 39 reduced holdings. 20 funds opened positions while 34 raised stakes. 55.48 million shares or 3.48% more from 53.61 million shares in 2018Q4 were reported. 250,887 were reported by Bancorporation Of Mellon Corporation. Great West Life Assurance Comm Can holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 8,003 shares. Aqr Capital Limited Co, a Connecticut-based fund reported 33,772 shares. Neuberger Berman Limited Liability Corp reported 60,000 shares. Legal & General Group Public Ltd Liability owns 11,732 shares. 5,000 were reported by Parallax Volatility Advisers L P. Deutsche Bancorporation Ag holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 121,640 shares. Alliancebernstein Lp holds 0% or 59,800 shares in its portfolio. Doheny Asset Mngmt Ca accumulated 0.41% or 27,450 shares. Cubist Systematic Strategies Limited Liability Com accumulated 2,862 shares. Rhumbline Advisers reported 80,220 shares. Renaissance Technologies Llc holds 0% or 79,662 shares in its portfolio. Blackrock Incorporated invested in 5.19 million shares. Metropolitan Life Insur Co New York owns 34,577 shares. James Inv has 645 shares.

Artal Group Sa decreased its stake in Fate Therapeutics Inc (FATE) by 16.28% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa sold 350,000 shares as the company’s stock rose 35.11% . The institutional investor held 1.80M shares of the health care company at the end of 2019Q1, valued at $31.63M, down from 2.15M at the end of the previous reported quarter. Artal Group Sa who had been investing in Fate Therapeutics Inc for a number of months, seems to be less bullish one the $1.15B market cap company. The stock decreased 1.62% or $0.29 during the last trading session, reaching $17.59. About 443,930 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 152.00% since August 15, 2018 and is uptrending. It has outperformed by 152.00% the S&P500.

Artal Group Sa, which manages about $2.45 billion US Long portfolio, upped its stake in Acceleron Pharma Inc (NASDAQ:XLRN) by 1.45 million shares to 1.65 million shares, valued at $76.84M in 2019Q1, according to the filing. It also increased its holding in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 150,000 shares in the quarter, for a total of 450,000 shares, and has risen its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO).

More notable recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Seekingalpha.com which released: “Affimed: Put This Company On Your Watch List – Seeking Alpha” on August 01, 2019, also Nasdaq.com with their article: “Interesting FATE Put And Call Options For July 19th – Nasdaq” published on May 21, 2019, Nasdaq.com published: “Factors Likely to Decide Gap’s (GPS) Fate in Q1 Earnings – Nasdaq” on May 23, 2019. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) were released by: Finance.Yahoo.com and their article: “Is Fate Therapeutics Inc (FATE) A Good Stock To Buy? – Yahoo Finance” published on May 03, 2019 as well as Nasdaq.com‘s news article titled: “Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? – Nasdaq” with publication date: February 25, 2019.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 4 analysts covering Fate Therapeutics (NASDAQ:FATE), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Fate Therapeutics has $2700 highest and $12 lowest target. $20.60’s average target is 17.11% above currents $17.59 stock price. Fate Therapeutics had 12 analyst reports since March 6, 2019 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, March 6 by H.C. Wainwright. The rating was maintained by Wells Fargo on Wednesday, March 6 with “Buy”.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.